|
pubmed:abstractText |
In the therapeutic schemes of the hormone-dependent gynecologic cancers, the combined administration of tamoxifen and medroxyprogesterone, generally, scores better results. The highly hormone-dependent tumors (ER+, PgR+) respond very well to a combined, simultaneous treatment. The strictly hormone-dependent (ER+, PgR-) and the potentially hormone-dependent (ER-, PgR-) tumors seem to be most efficiently treated by means of a combined, successive scheme.
|
